Financial Data and Key Metrics Changes - Total expenses increased approximately 3% year-over-year to $8.3 million in 2025, compared to $8.1 million in 2024 [15] - Research and development expenses rose to $5 million in 2025 from $4.4 million in 2024, a 13% increase primarily due to trial activities and regulatory efforts [15] - Selling, general and administrative expenses decreased 10% to $3.3 million in 2025 from $3.7 million in 2024 [16] - Net loss increased modestly to $8.2 million in 2025 from $7.9 million in 2024 [16] - Cash and cash equivalents totaled $2.5 million at the end of 2025, comparable to $2.4 million at the end of 2024 [16] Business Line Data and Key Metrics Changes - The lead program remains the CardiAMP cell therapy targeting ischemic heart failure, with significant clinical trial data supporting its efficacy [4][5] - The CardiAMP HF trial showed reductions in left ventricular volume with p-values approaching significance, particularly in subgroups with elevated biomarkers of heart stress [6][28] Market Data and Key Metrics Changes - The U.S. market for ischemic heart failure includes approximately 1 million patients, with Japan having around 150,000 patients [4] - Recent developments in Japan include conditional approval for another allogeneic cell therapy for ischemic heart failure, indicating a competitive landscape [10] Company Strategy and Development Direction - The company aims to advance its CardiAMP and CardiALLO therapies while seeking regulatory approvals in the U.S. and Japan [12][14] - The strategy includes engaging with regulatory bodies for potential near-term approvals and completing the CardiAMP HF II confirmatory clinical study [62] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the clinical data supporting CardiAMP therapy and its potential to address significant unmet needs in heart failure [7][29] - The company anticipates a consistent cash burn in 2026 while managing resources carefully [16] Other Important Information - The company has four upcoming catalysts, including FDA submissions and clinical consultations with Japan's PMDA [12][13] - The CardiAMP HF II trial is designed to focus on the most responsive patient subgroups, leveraging learnings from previous trials [11] Q&A Session Summary Question: Can you provide insights on the echo data presented at THT? - Management noted that while p-values for the complete population were not statistically significant, they were approaching significance, particularly in subgroups with elevated NT-proBNP [25][26] Question: What is the timeline for the CardiAMP submission to the FDA? - The company expects to file for a discussion on approvable pathways imminently, with a potential 45-day turnaround for feedback from the FDA [30] Question: How is enrollment in the HF II trial progressing? - Enrollment is starting slowly due to resource allocation towards regulatory submissions, but interest from clinical sites is strong [53] Question: How does CardiAMP HF compete with other cell therapies? - Management believes CardiAMP will remain a leading therapy due to its straightforward and cost-effective nature, despite the competitive landscape [41][43]

Financial Data and Key Metrics Changes - Total expenses increased approximately 3% year-over-year to $8.3 million in 2025, compared to $8.1 million in 2024 [15] - Research and development expenses rose to $5 million in 2025 from $4.4 million in 2024, a 13% increase primarily due to trial activities and regulatory efforts [16] - Selling, general and administrative expenses decreased 10% to $3.3 million in 2025 from $3.7 million in 2024 [17] - Net loss increased modestly to $8.2 million in 2025 from $7.9 million in 2024 [17] - Cash and cash equivalents totaled $2.5 million at year-end 2025, comparable to $2.4 million at the end of 2024 [17] Business Line Data and Key Metrics Changes - The CardiAMP cell therapy program is focused on treating ischemic heart failure, with significant clinical trial data supporting its efficacy [4][5] - The CardiAMP HF trial showed reductions in left ventricular volume with p-values approaching significance, indicating potential benefits for patients with elevated biomarkers of heart stress [6][9] Market Data and Key Metrics Changes - The U.S. market for ischemic heart failure treatment includes approximately 1 million patients, with Japan accounting for around 150,000 patients [4] - Recent developments in Japan include conditional approval for another allogeneic cell therapy for ischemic heart failure, indicating a competitive landscape [11] Company Strategy and Development Direction - The company aims to advance its CardiAMP and CardiALLO therapies while seeking regulatory approvals in the U.S. and Japan [10][13] - The strategy includes engaging with regulatory bodies for potential near-term approvals and initiating confirmatory studies to support ongoing clinical development [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming regulatory discussions and the potential for early approval of CardiAMP therapies [33][70] - The company anticipates that the data from clinical trials will drive enrollment in future studies and enhance interest from cardiologists [32][63] Other Important Information - The company has four key catalysts expected in the next quarter, including submissions to the FDA and consultations with Japan's PMDA [13] - The CardiAMP HF II trial is designed to focus on the most responsive patient subgroups, leveraging insights from previous trials [12] Q&A Session Summary Question: Can you provide insights on the echo data presented at THT? - Management noted that while the overall p-values were not statistically significant, they were approaching significance, particularly in subgroups with elevated NT-proBNP [29][30] Question: What is the timeline for the CardiAMP submission to the FDA? - The company expects to file for a discussion on approvable pathways imminently, with a turnaround time of approximately 45 days due to the breakthrough designation [34][35] Question: How is enrollment in the HF2 trial progressing? - Enrollment is starting slowly as the clinical team focuses on regulatory submissions, but interest from multiple sites is expected to drive future enrollment [63]

Core Insights - BioCardia, Inc. reported financial results for Q1 2025, highlighting advancements in its cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases [1][8] Recent Business Highlights - The CardiAMP autologous cell therapy for ischemic heart failure (BCDA-01) showed a 107-second increase in exercise tolerance and an 82% reduction in angina episodes at the six-month follow-up [2] - The CardiALLO cell therapy (BCDA-03) completed a low dose cohort with no adverse events, and the independent Data Safety Monitoring Board recommended proceeding with the study [3] - The Helix biotherapeutic delivery system demonstrated safety in the CardiAMP HF Trial, with no procedure-related deaths or complications, supporting FDA approval efforts [3] Intellectual Property - BioCardia holds over 60 patents and applications globally, with a recent patent granted in Japan for a delivery catheter that enhances minimally invasive treatment options [5][6] Financial Results - Research and development expenses increased to approximately $1.5 million in Q1 2025 from $1.2 million in Q1 2024, while selling, general, and administrative expenses rose to approximately $1.2 million from $1.1 million [11] - The net loss for Q1 2025 was approximately $2.7 million, compared to $2.3 million in Q1 2024, with net cash used in operations at approximately $1.6 million [11][15] Upcoming Milestones - The company plans to submit data to the FDA and Japan PMDA regarding the CardiAMP cell therapy and Helix delivery system, with additional enrollment in the CardiAMP HF II Trial [9][11]